- Home
- IMCR vs FRME Comparison
IMCR vs FRME Comparison
Compare IMCR & FRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- FRME
- Stock Information
- Founded
- IMCR 2008
- FRME 1893
- Country
- IMCR United Kingdom
- FRME United States
- Employees
- IMCR N/A
- FRME N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- FRME Major Banks
- Sector
- IMCR Health Care
- FRME Finance
- Exchange
- IMCR Nasdaq
- FRME Nasdaq
- Market Cap
- IMCR 1.8B
- FRME 2.3B
- IPO Year
- IMCR 2021
- FRME N/A
- Fundamental
- Price
- IMCR $34.69
- FRME $39.95
- Analyst Decision
- IMCR Buy
- FRME Buy
- Analyst Count
- IMCR 8
- FRME 3
- Target Price
- IMCR $57.00
- FRME $46.67
- AVG Volume (30 Days)
- IMCR 281.5K
- FRME 200.2K
- Earning Date
- IMCR 11-05-2025
- FRME 10-23-2025
- Dividend Yield
- IMCR N/A
- FRME 3.60%
- EPS Growth
- IMCR N/A
- FRME 23.41
- EPS
- IMCR N/A
- FRME 3.85
- Revenue
- IMCR $356,145,000.00
- FRME $638,723,000.00
- Revenue This Year
- IMCR $31.83
- FRME $14.55
- Revenue Next Year
- IMCR $8.50
- FRME $4.19
- P/E Ratio
- IMCR N/A
- FRME $10.39
- Revenue Growth
- IMCR 26.78
- FRME 6.22
- 52 Week Low
- IMCR $23.15
- FRME $33.13
- 52 Week High
- IMCR $39.33
- FRME $46.13
- Technical
- Relative Strength Index (RSI)
- IMCR 52.51
- FRME 46.74
- Support Level
- IMCR $35.33
- FRME $39.93
- Resistance Level
- IMCR $36.76
- FRME $40.54
- Average True Range (ATR)
- IMCR 1.34
- FRME 0.78
- MACD
- IMCR 0.17
- FRME -0.20
- Stochastic Oscillator
- IMCR 44.72
- FRME 5.05
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.